TR200400621T2 - GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. - Google Patents

GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Info

Publication number
TR200400621T2
TR200400621T2 TR2004/00621T TR200400621T TR200400621T2 TR 200400621 T2 TR200400621 T2 TR 200400621T2 TR 2004/00621 T TR2004/00621 T TR 2004/00621T TR 200400621 T TR200400621 T TR 200400621T TR 200400621 T2 TR200400621 T2 TR 200400621T2
Authority
TR
Turkey
Prior art keywords
gdf
methods
vaccination
analogs
homologous
Prior art date
Application number
TR2004/00621T
Other languages
English (en)
Inventor
Halkier Torben
Mouritsen S�ren
Klysner Steen
Original Assignee
Pharmexa A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S filed Critical Pharmexa A/S
Publication of TR200400621T2 publication Critical patent/TR200400621T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of Eletrric Generators (AREA)
  • Debugging And Monitoring (AREA)

Abstract

Büyüme farklilasmasi faktörü 8'e (GDF-8, miyostatin) karsi bagisiklik kazandirarak kas kütlesinin arttirilmasi için yeni yöntemler açiklanmistir. Bagisiklik kazandirma tercihen homolog GDF-8'e karsi antikor üretimini baslatabilen GDF-8 analoglarinin uygulanmasiyla gerçeklestirilir. Immünojen olarak özellikle tercih edilen, homolog GDF-8'in üçüncül yapisini büyük ölçüde korurken, bir veya birkaç yabanci, immünodominant ve ayrimsiz T-hücresi epitopunun sokulmasiyla modifiye edilmis olan homolog GDF-8'dir. Yine, GDF-8'e karsi nükleik asit asilama ve canli asilari kullanarak yapilan asilamanin yani sira, asilama için faydali yöntemler ve vasitalar da açiklanmistir. Bu yöntemler ve vasitalar, faydali immünojenik GDF-8 analoglarinin tanimlanmasi için yöntemleri, analoglarin ve farmasötik formülasyonlarin hazirlanmasi için yöntemleri, ayrica nükleik asit parçalarini, vektörleri, transforme edilmis hücreleri, polipeptitleri ve farmasötik formülasyonlari içerir.
TR2004/00621T 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. TR200400621T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26

Publications (1)

Publication Number Publication Date
TR200400621T2 true TR200400621T2 (tr) 2004-08-23

Family

ID=26065065

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2004/00621T TR200400621T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
TR2002/00133T TR200200133T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/00133T TR200200133T2 (tr) 1999-07-20 2000-07-20 GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.

Country Status (21)

Country Link
US (2) US7056512B1 (tr)
EP (1) EP1200119A2 (tr)
JP (1) JP2003506325A (tr)
KR (1) KR100750695B1 (tr)
CN (1) CN1384757A (tr)
AU (1) AU778470B2 (tr)
CA (1) CA2379852A1 (tr)
EA (1) EA005248B1 (tr)
EE (1) EE200200025A (tr)
HK (1) HK1048937A1 (tr)
HR (1) HRP20010900A2 (tr)
HU (1) HUP0201861A3 (tr)
IL (1) IL146845A0 (tr)
MX (1) MXPA01013232A (tr)
NO (1) NO20016252L (tr)
NZ (1) NZ517058A (tr)
PL (1) PL353855A1 (tr)
SK (1) SK722002A3 (tr)
TR (2) TR200400621T2 (tr)
WO (1) WO2001005820A2 (tr)
ZA (1) ZA200109901B (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
AU765214B2 (en) * 1998-05-06 2003-09-11 Metamorphix International, Inc. Methods for treating diabetes by inhibiting gdf-8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
US7785587B2 (en) 2003-06-02 2010-08-31 Wyeth Therapeutic methods for muscular or neuromuscular disorders
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
US7371726B2 (en) * 2003-12-31 2008-05-13 Schering-Plough Animal Health Corporation Neutralizing GDF8 epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2006036074A1 (en) 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
CA2693378C (en) 2006-08-03 2020-04-14 Orico Limited Myostatin antagonists
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2013003983A1 (zh) * 2011-07-06 2013-01-10 湖北省农业科学院畜牧兽医研究所 猪肌抑素基因座位及其应用
RS56796B1 (sr) 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
NZ702269A (en) 2012-06-15 2017-07-28 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
EP3711771A1 (en) 2012-08-01 2020-09-23 Ikaika Therapeutics, LLC Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
JP2016521283A (ja) 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 成長因子モジュレーションのための組成物および方法
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
CN107771081A (zh) 2015-04-15 2018-03-06 瑞泽恩制药公司 用gdf8抑制剂增加力量和功能的方法
CA3092334A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
CN1178955C (zh) 1997-04-15 2004-12-08 法默卡有限公司 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
JP4368522B2 (ja) 1997-07-14 2009-11-18 ユニバーシティー オブ リージ 哺乳動物におけるダブルマスル化を引き起こすミオスタチン遺伝子の変異
JP2003528024A (ja) * 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
NZ517058A (en) 2004-04-30
KR20020026544A (ko) 2002-04-10
ZA200109901B (en) 2003-05-28
MXPA01013232A (es) 2005-05-24
JP2003506325A (ja) 2003-02-18
CN1384757A (zh) 2002-12-11
NO20016252L (no) 2002-03-15
HK1048937A1 (zh) 2003-04-25
EP1200119A2 (en) 2002-05-02
US7070784B1 (en) 2006-07-04
AU5967500A (en) 2001-02-05
HUP0201861A3 (en) 2004-07-28
IL146845A0 (en) 2002-07-25
WO2001005820A2 (en) 2001-01-25
SK722002A3 (en) 2003-02-04
HUP0201861A2 (en) 2002-09-28
US7056512B1 (en) 2006-06-06
WO2001005820A3 (en) 2001-07-19
CA2379852A1 (en) 2001-01-25
EE200200025A (et) 2003-04-15
AU778470B2 (en) 2004-12-09
HRP20010900A2 (en) 2003-08-31
EA200200182A1 (ru) 2002-06-27
TR200200133T2 (tr) 2002-05-21
EA005248B1 (ru) 2004-12-30
NO20016252D0 (no) 2001-12-19
KR100750695B1 (ko) 2007-08-22
PL353855A1 (en) 2003-12-01

Similar Documents

Publication Publication Date Title
TR200400621T2 (tr) GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
NO20023961D0 (no) Ny fremgangsmåte for nedregulering av amyloid
EP1108035B1 (en) Treatment of cervical cancer
RU2015139827A (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
MXPA02007796A (es) Metodo novedoso para la disminucion de cuerpos amiloides.
BenMohamed et al. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses
JP2011168611A (ja) 髄膜炎菌類タンパク質ｎｍｂ１８７０のドメインおよびエピトープ
CA2325566A1 (en) Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
WO2000020027A3 (en) Methods for therapeutic vaccination
CA2457140A1 (en) Beta-amyloid-analogue - t-cell epitope vaccine
JPH03173830A (ja) ワクチン組成物
US20220378895A1 (en) Novel immunogens and methods for discovery and screening thereof
EP1266662A2 (en) Synthetic peptide vaccines for dental caries
JP3881514B2 (ja) クラミジア感染症に対するｄｎａ免疫化
JP2002542264A (ja) 核酸による免疫化
AU2002233166B2 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
Menon et al. Mycobacterial ESAT-6 protein enhances mouse IFN-γ responses to Mycoplasma hyopneumoniae P71 protein
MY135691A (en) Method for down-regulation of gdf-8 activity
Riedmiller et al. Mosaic and cocktail capsid-virus-like particle vaccines for induction of antibodies against the EPCR-binding CIDRα1 domain of PfEMP1
EP1502602A3 (en) Methods for therapeutic vaccination
ECSP003580A (es) Metodos nuevos para aumentar la masa muscular mediante la inmunizacion contra el gdf-8